Herceptin’s Salivary Cancer Use Sails through PAFSC; Label Expansions for I/O Drugs, Lorbrena in Line for Approval

A health ministry advisory panel on November 4 backed approval for additional orphan indications for two drugs, Chugai Pharmaceutical’s cancer medicine Herceptin (trastuzumab) and HUYA Japan’s oral histone deacetylase (HDAC) inhibitor Hiyasta (tucidinostat). The Pharmaceutical Affairs and Food Sanitation Council’s...read more